EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancements in Viral Gene Therapy for Gaucher Disease

Akhil Kulkarni, Tiffany Chen, Ellen Sidransky, Tae-Un Han

Genes · 2024

DOI: 10.3390/genes15030364 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2024. Verfasst von Akhil Kulkarni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, Building 35A, Room 1E623, 35A Convent Drive, M…. Hauptthemen laut MEDLINE: Gaucher Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Human Genome Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gaucher disease, an autosomal recessively inherited lysosomal storage disorder, results from biallelic mutations in the GBA1 gene resulting in deficient activity of the enzyme glucocerebrosidase. In Gaucher disease, the reduced levels and activity of glucocerebrosidase lead to a disparity in the rates of formation and breakdown of glucocerebroside and glucosylsphingosine, resulting in the accumulation of these lipid substrates in the lysosome. This gives rise to the development of Gaucher cells, engorged macrophages with a characteristic wrinkled tissue paper appearance. There are both non-neuronopathic (type 1) and neuronopathic (types 2 and 3) forms of Gaucher disease, associated with varying degrees of severity. The visceral and hematologic manifestations of Gaucher disease respond well to both enzyme replacement therapy and substrate reduction therapy. However, these therapies do not improve the neuronopathic manifestations, as they cannot cross the blood–brain barrier. There is now an established precedent for treating lysosomal storage disorders with gene therapy strategies, as many have the potential to cross into the brain. The range of the gene therapies being employed is broad, but this review aimed to discuss the progress, advances, and challenges in developing viral gene therapy as a treatment for Gaucher disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gaucher DiseaseHumansGlucosylceramidaseBrainBlood-Brain BarrierMacrophages

Stichwörter der Autor:innen

AAVGaucher diseasegene therapymurine modelstherapeuticsvector

Substanzen

Glucosylceramidase

Autor:innen und Institutionen

  • Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, Building 35A, Room 1E623, 35A Convent Drive, MSC 3708, Bethesda, MD 20892-3708, USA.

Förderung

  • NIH HHS
  • National Human Genome Institute
  • National Institutes of Health

Zitieren

APA

Kulkarni, A., Chen, T., Sidransky, E., & Han, T. U. (2024). Advancements in Viral Gene Therapy for Gaucher Disease. Genes. https://doi.org/10.3390/genes15030364

Vancouver

Kulkarni A, Chen T, Sidransky E, Han TU. Advancements in Viral Gene Therapy for Gaucher Disease. Genes. 2024. doi:10.3390/genes15030364

BibTeX
@article{Kulkarni2024,
  author = {Kulkarni, Akhil and Chen, Tiffany and Sidransky, Ellen and Han, Tae-Un},
  title = {Advancements in Viral Gene Therapy for Gaucher Disease},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15030364}
}
Kostenlos starten →